Page 29 - Read Online
P. 29

Page 10 of 12     Mansinho et al. J Cancer Metastasis Treat 2021;7:44  https://dx.doi.org/10.20517/2394-4722.2021.88

               Ethical approval and consent to participate
               Not applicable.


               Consent for publication
               Not applicable.


               Copyright
               © The Author(s) 2021.


               REFERENCES
               1.       Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol 2004;22:4991-5004.  DOI  PubMed
               2.       Gong J, Maia MC, Dizman N, Govindarajan A, Pal SK. Metastasis in renal cell carcinoma: biology and implications for therapy. Asian
                   J Urol 2016;3:286-92.  DOI  PubMed  PMC
               3.       Grange C, Tapparo M, Collino F, et al. Microvesicles released from human renal cancer stem cells stimulate angiogenesis and
                   formation of lung premetastatic niche. Cancer Res 2011;71:5346-56.  DOI  PubMed
               4.       Razorenova OV, Finger EC, Colavitti R, et al. VHL loss in renal cell carcinoma leads to up-regulation of CUB domain-containing
                   protein 1 to stimulate PKC{delta}-driven migration. Proc Natl Acad Sci U S A 2011;108:1931-6.  DOI  PubMed  PMC
               5.       Aubert S, Fauquette V, Hémon B, et al. MUC1, a new hypoxia inducible factor target gene, is an actor in clear renal cell carcinoma
                   tumor progression. Cancer Res 2009;69:5707-15.  DOI  PubMed
               6.       Struckmann K, Mertz K, Steu S, et al. pVHL co-ordinately regulates CXCR4/CXCL12 and MMP2/MMP9 expression in human clear-
                   cell renal cell carcinoma. J Pathol 2008;214:464-71.  DOI  PubMed
               7.       Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev 1989;8:98-101.  PubMed
               8.       Bianchi M, Sun M, Jeldres C, et al. Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol
                   2012;23:973-80.  DOI  PubMed
               9.       Choueiri TK, Powles T, Burotto M, et al; CheckMate 9ER Investigators. Nivolumab plus cabozantinib versus sunitinib for advanced
                   renal-cell carcinoma. N Engl J Med 2021;384:829-41.  DOI  PubMed
               10.      Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med
                   2019;380:1103-15.  DOI  PubMed  PMC
               11.      Rini BI, Plimack ER, Stus V, et al; KEYNOTE-426 Investigators. Pembrolizumab plus axitinib versus sunitinib for advanced renal-
                   cell carcinoma. N Engl J Med 2019;380:1116-27.  DOI  PubMed
               12.      Motzer RJ, Tannir NM, McDermott DF, et al; CheckMate 214 Investigators. Nivolumab plus Ipilimumab versus Sunitinib in advanced
                   renal-cell carcinoma. N Engl J Med 2018;378:1277-90.  DOI  PubMed  PMC
               13.      Motzer RJ, Alekseev B, Rha SY, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med
                   2021;384:1289-300.  DOI  PubMed
               14.      Kinnane N. Burden of bone disease. Eur J Oncol Nurs 2007;11 Suppl 2:S28-31.  DOI  PubMed
               15.      Beuselinck B, Oudard S, Rixe O, et al. Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with
                   sunitinib. Ann Oncol 2011;22:794-800.  DOI  PubMed
               16.      Santoni M, Conti A, Procopio G, et al. Bone metastases in patients with metastatic renal cell carcinoma: are they always associated
                   with poor prognosis? J Exp Clin Cancer Res 2015;34:10.  DOI  PubMed  PMC
               17.      Yuasa T, Urakami S, Yamamoto S, et al. Treatment outcome and prognostic factors in renal cell cancer patients with bone metastasis.
                   Clin Exp Metastasis 2011;28:405-11.  DOI  PubMed
               18.      Chen SC, Kuo PL. Bone metastases from renal cell carcinoma. Int J Mol Sci 2016;17:987.
               19.      Kume H, Kakutani S, Yamada Y, et al. Prognostic factors for renal cell carcinoma with bone metastasis: who are the long-term
                   survivors? J Urol 2011;185:1611-4.  DOI  PubMed
               20.      Grünwald V, Eberhardt B, Bex A, et al. An interdisciplinary consensus on the management of bone metastases from renal cell
                   carcinoma. Nat Rev Urol 2018;15:511-21.  DOI  PubMed  PMC
               21.      Kang M, Choi J, Kim J, et al. Prognostic impact of bone metastasis on survival outcomes in patients with metastatic renal cell
                   carcinoma treated by first line tyrosine kinase inhibitors: a propensity-score matching analysis. J Cancer 2020;11:7202-8.  DOI
                   PubMed  PMC
               22.      Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 2006;12:895-904.  DOI  PubMed
               23.      Wang J, Shiozawa Y, Wang J, et al. The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J Biol
                   Chem 2008;283:4283-94.  DOI  PubMed
               24.      Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. Nat Rev Cancer 2011;11:411-25.  DOI  PubMed  PMC
               25.      Trouvin AP, Goëb V. Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss.
                   Clin Interv Aging 2010;5:345-54.  DOI  PubMed  PMC
               26.      Dougall WC, Glaccum M, Charrier K, et al. RANK is essential for osteoclast and lymph node development. Genes Dev 1999;13:2412-
                   24.  DOI  PubMed  PMC
               27.      Casimiro S, Ferreira AR, Mansinho A, Alho I, Costa L. Molecular mechanisms of bone metastasis: which targets came from the bench
                   to the bedside? Int J Mol Sci 2016;17:1415.  DOI  PubMed  PMC
   24   25   26   27   28   29   30   31   32   33   34